title: Comparison of medication practices in patients with heart failure and preserved versus those with reduced ejection fraction (from the Cardiovascular Research Network [CVRN]).
abstract: Limited data exist describing the differences in the medical treatment of patients with heart failure with preserved ejection fraction (HF-PEF) from those with heart failure with reduced ejection fraction (HF-REF) in more generalizable population-based cohorts. We studied patients with incident HF diagnosed from 2005 to 2008 from 4 sites participating in the Cardiovascular Research Network. These patients, their medication profile, and left ventricular systolic function status were identified from the hospital discharge and ambulatory visit diagnoses, pharmacy dispensing information, and imaging reports found in the health plan electronic databases and through chart review. The study population consisted of 6,210 patients with newly diagnosed HF-PEF and 3,914 patients with newly diagnosed HF-REF. The mean age of our study population was 73 years, 48% were women, and 74% were white. The patients with HF-REF were less likely to have been treated with various cardiac and HF-related medications before their index HF event; however, they were significantly more likely to have been treated with new cardiac medications and HF therapies after the diagnosis of HF than were the patients with HF-PEF. After controlling for several potentially confounding factors, the patients with HF-PEF were significantly less likely to have been treated with multiple cardiac drug regimens (adjusted odds ratio 0.69, 95% confidence interval 0.59 to 0.81) and multiple HF-related therapies (adjusted odds ratio 0.40, 95% confidence interval 0.38 to 0.42) than were patients with HF-REF. In conclusion, the present results from a large, population-based sample suggest considerable variation in the previous and new use of different cardiac medication classes of drugs in patients with HF-PEF versus HF-REF.
authors: Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, USA. Robert.Goldberg@umassmed.edu
authors: Robert J
authors: RJ
authors: Goldberg
authors: Jerry H
authors: JH
authors: Gurwitz
authors: Jane S
authors: JS
authors: Saczynski
authors: Grace
authors: G
authors: Hsu
authors: David D
authors: DD
authors: McManus
authors: David J
authors: DJ
authors: Magid
authors: David H
authors: DH
authors: Smith
authors: Alan S
authors: AS
authors: Go
mesh_terms: D000368:Aged; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology; D006801:Humans; D015994:Incidence; D008297:Male; D011159:Population Surveillance; D011379:Prognosis; D012189:Retrospective Studies; D013318:Stroke Volume; D014481:United States / Q000453:epidemiology; D016277:Ventricular Function, Left / Q000502:physiology*
chemical_list: D002316:Cardiotonic Agents
references: Am Heart J. 2011 Dec;162(6):966-972.e10
references: 22137068
references: Circ Cardiovasc Qual Outcomes. 2008 Nov;1(2):138-47
references: 20031802
references: JAMA. 2003 Jan 8;289(2):194-202
references: 12517230
references: J Am Coll Cardiol. 2004 Feb 4;43(3):317-27
references: 15013109
references: J Am Coll Cardiol. 2007 Aug 21;50(8):768-77
references: 17707182
references: N Engl J Med. 1997 Feb 20;336(8):525-33
references: 9036306
references: N Engl J Med. 2008 Dec 4;359(23):2456-67
references: 19001508
references: Circulation. 2009 Apr 14;119(14):e391-479
references: 19324966
references: Circulation. 2003 Feb 11;107(5):656-8
references: 12578861
references: JAMA. 2006 Nov 1;296(17):2105-11
references: 17077375
references: J Am Coll Cardiol. 2006 Jan 3;47(1):76-84
references: 16386668
references: J Am Coll Cardiol. 2012 Dec 11;60(23):2349-56
references: 23141494
references: Circulation. 2012 Jul 3;126(1):65-75
references: 22615345
references: N Engl J Med. 2004 Sep 23;351(13):1296-305
references: 15385656
references: J Card Fail. 2006 Feb;12(1):e1-2
references: 16500560
references: J Am Coll Cardiol. 2001 Nov 1;38(5):1277-82
references: 11691495
references: Eur Heart J. 2007 May;28(9):1128-34
references: 17459902
references: N Engl J Med. 2004 Sep 9;351(11):1097-105
references: 15356307
references: Expert Rev Cardiovasc Ther. 2008 Sep;6(8):1043-5
references: 18793105
references: N Engl J Med. 2006 Jul 20;355(3):260-9
references: 16855266
references: JAMA. 2006 Nov 8;296(18):2209-16
references: 17090767
references: Lancet. 2003 Sep 6;362(9386):777-81
references: 13678871
references: JAMA. 2012 Nov 28;308(20):2108-17
references: 23188027
references: N Engl J Med. 1971 Dec 23;285(26):1441-6
references: 5122894
references: N Engl J Med. 2006 Jul 20;355(3):251-9
references: 16855265